Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06335069

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer - a Pilot Study.

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Maastricht University Medical Center · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The extent of breast cancer is an important prognostic factor in patients diagnosed with this disease. Therefore, adequate staging at diagnosis is a requisite for optimal treatment. In all patients diagnosed with locally advanced breast cancer (LABC), distant staging using 18F-FDG PET/CT is recommended. However, the degree of metabolic uptake in the primary breast tumor is significantly lower in the ER+ subtype compared to HER2+ and triple negative breast cancer (TNBC). As a consequence, a suboptimal 18F-FDG uptake in ER+ breast cancer patients can potentially lead to missed distant metastases. Fibroblast-activating protein inhibitor (FAPI) is a recently developed radiotracer that binds to FAP, a stromal antigen overexpressed in more than 90% of epithelial-derived tumors and their metastases. Previous studies all show 68Ga-FAPI PET/CT to have a higher detection rate compared to 18F-FDG PET/CT. However, all previous studies were performed without considering breast cancer subtype. If the metabolic uptake by 68Ga-FAPI-46 is higher in ER+ breast cancer patients, more lesions will be detected, resulting in a more appropriate treatment for these patients. Therefore, in this pilot study, the investigators aim to compare the diagnostic performance of 18F-FDG with 68Ga-FAPI-46 as PET-tracer in ER+ breast cancer patients.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TEST68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRIAll participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.

Timeline

Start date
2025-09-01
Primary completion
2027-03-01
Completion
2027-03-01
First posted
2024-03-28
Last updated
2025-09-24

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06335069. Inclusion in this directory is not an endorsement.